ArticleEJNMMI research2025
Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer.
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials.Cancer innovation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEpithelial ovarian cancer (EOC) has the highest mortality rate among gynecological malignancies, primarily due to frequent late-stage diagnosis and the development of resistance to chemotherapy. The aim of this study was to evaluate the expression of tumor-associated targets in a large cohort (n = 179) of various EOC subtypes, represented on two tissue microarrays (TMAs), to support the future development of radionuclide therapies. The study primarily assessed folate receptor-alpha and -beta isoforms (FRα and FRβ), but also somatostatin receptor-2 (SSTR2), prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP), for which established radiopharmaceuticals already exist. Membranous expression of these targets on tumor cells was detected by immunohistochemistry using antibodies validated on xenografts with known target expression and semi-quantitatively evaluated.
resultsValidation of the employed antibodies confirmed specific staining of the respective targets. The TMAs included tumors of high-grade and low-grade serous, endometrioid, clear cell, mucinous and carcinosarcoma. High FRα expression was seen in several EOC histotypes, most frequently in high-grade serous (47%), while it was largely absent in mucinous EOC. The FRβ was expressed only in stromal cells. SSTR2 and PSMA were only present in 8% and 4% of the EOC cases and not associated to a specific subtype. FAP expression on tumor cells was found in 10% of all EOCs, while stromal FAP was seen in 47% of the cases, with the highest prevalence in high-grade serous EOC (42%).
conclusionsThe findings of this study indicate that approved radionuclide therapies targeting SSTR2 or PSMA are unlikely to be suitable for treating EOC. In contrast, the frequent and high expression of FRα in tumor cells and FAP in tumor-associated stromal cells suggests that FRα- and FAP-targeted radiopharmaceuticals hold promise for the treatment of advanced-stage EOC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.